Evaluating oxygen levels for embryo development in IVF
Can a Differentiated Oxygen Setup Improve Embryo Quality and Increase the Number of Usable Embryos After in Vitro Fertilization (IVF)?
This study is testing whether using different oxygen levels during IVF can help embryos develop better for women undergoing fertility treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years to 41 Years |
| Sex | Female |
| Sponsor | Odense University Hospital Academic / other |
| Locations | 1 site (Odense) |
| Trial ID | NCT05737381 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the impact of different oxygen tensions on the development of human embryos during in vitro fertilization (IVF). It is a prospective, interventional multicenter study that utilizes sibling embryos from women aged 18-41 with normal weight undergoing assisted reproductive technology. Participants will follow standard IVF protocols, with oocytes divided into two groups: one group will be incubated at 5% oxygen and the other at 2% oxygen after three days. The study will also measure reactive oxygen species levels in the spent media from developing blastocysts.
Who should consider this trial
Good fit: Ideal candidates are women aged 18-41 with a normal BMI who are undergoing IVF or ICSI and have at least 8 oocytes retrieved.
Not a fit: Patients with sperm from testes biopsy, congenital uterine abnormalities, fibromas, polyps, or suspected hydrosalpinges may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve embryo quality and increase the chances of successful pregnancies in IVF treatments.
How similar studies have performed: While the specific approach of differential oxygen tension is being explored, similar studies have shown promise in optimizing embryo culture conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients undergoing assisted reproductive technology (ART), with planned IVF or intracytoplasmic sperm injection (ICSI) cycles. Women age 18 - 41 years and BMI 18 - 35 kg/m2 (both inclusive) with ≥ 8 oocytes. Patients will be included no later than at oocyte pick-up. Exclusion Criteria: Patients with sperm from testes biopsy, congenital uterine abnormalities, presence of fibromas or polyps, or suspected hydro salpinges. Oocytes from donors.
Where this trial is running
Odense
- Odense University Hospital — Odense, Denmark (Recruiting)
Study contacts
- Principal investigator: Tilde Eskildsen — Odense University Hospital
- Study coordinator: Tilde Eskildsen
- Email: tilde.veng.eskildsen@rsyd.dk
- Phone: +4565412324
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.